S&P 500   5,107.42 (+0.22%)
DOW   38,984.10 (-0.03%)
QQQ   441.83 (+0.64%)
AAPL   178.68 (-1.15%)
MSFT   412.41 (-0.30%)
META   500.47 (+2.11%)
GOOGL   137.71 (-0.54%)
AMZN   177.03 (+0.15%)
TSLA   199.90 (-0.98%)
NVDA   807.88 (+2.12%)
NIO   5.75 (+0.00%)
AMD   200.15 (+3.96%)
BABA   74.55 (+0.70%)
T   17.00 (+0.41%)
F   12.62 (+1.45%)
MU   95.09 (+4.94%)
CGC   3.17 (-3.65%)
GE   158.49 (+1.02%)
DIS   111.89 (+0.28%)
AMC   4.36 (+0.93%)
PFE   26.61 (+0.19%)
PYPL   61.63 (+2.14%)
XOM   105.80 (+1.22%)
S&P 500   5,107.42 (+0.22%)
DOW   38,984.10 (-0.03%)
QQQ   441.83 (+0.64%)
AAPL   178.68 (-1.15%)
MSFT   412.41 (-0.30%)
META   500.47 (+2.11%)
GOOGL   137.71 (-0.54%)
AMZN   177.03 (+0.15%)
TSLA   199.90 (-0.98%)
NVDA   807.88 (+2.12%)
NIO   5.75 (+0.00%)
AMD   200.15 (+3.96%)
BABA   74.55 (+0.70%)
T   17.00 (+0.41%)
F   12.62 (+1.45%)
MU   95.09 (+4.94%)
CGC   3.17 (-3.65%)
GE   158.49 (+1.02%)
DIS   111.89 (+0.28%)
AMC   4.36 (+0.93%)
PFE   26.61 (+0.19%)
PYPL   61.63 (+2.14%)
XOM   105.80 (+1.22%)
S&P 500   5,107.42 (+0.22%)
DOW   38,984.10 (-0.03%)
QQQ   441.83 (+0.64%)
AAPL   178.68 (-1.15%)
MSFT   412.41 (-0.30%)
META   500.47 (+2.11%)
GOOGL   137.71 (-0.54%)
AMZN   177.03 (+0.15%)
TSLA   199.90 (-0.98%)
NVDA   807.88 (+2.12%)
NIO   5.75 (+0.00%)
AMD   200.15 (+3.96%)
BABA   74.55 (+0.70%)
T   17.00 (+0.41%)
F   12.62 (+1.45%)
MU   95.09 (+4.94%)
CGC   3.17 (-3.65%)
GE   158.49 (+1.02%)
DIS   111.89 (+0.28%)
AMC   4.36 (+0.93%)
PFE   26.61 (+0.19%)
PYPL   61.63 (+2.14%)
XOM   105.80 (+1.22%)
S&P 500   5,107.42 (+0.22%)
DOW   38,984.10 (-0.03%)
QQQ   441.83 (+0.64%)
AAPL   178.68 (-1.15%)
MSFT   412.41 (-0.30%)
META   500.47 (+2.11%)
GOOGL   137.71 (-0.54%)
AMZN   177.03 (+0.15%)
TSLA   199.90 (-0.98%)
NVDA   807.88 (+2.12%)
NIO   5.75 (+0.00%)
AMD   200.15 (+3.96%)
BABA   74.55 (+0.70%)
T   17.00 (+0.41%)
F   12.62 (+1.45%)
MU   95.09 (+4.94%)
CGC   3.17 (-3.65%)
GE   158.49 (+1.02%)
DIS   111.89 (+0.28%)
AMC   4.36 (+0.93%)
PFE   26.61 (+0.19%)
PYPL   61.63 (+2.14%)
XOM   105.80 (+1.22%)

Imunon (IMNN) Competitors

$1.02
-0.12 (-10.50%)
(As of 10:21 AM ET)

IMNN vs. ALZN, GNPX, SHPH, CYCN, HILS, PULM, CLVR, VIRI, LIXT, and UPC

Should you be buying Imunon stock or one of its competitors? The main competitors of Imunon include Alzamend Neuro (ALZN), Genprex (GNPX), Shuttle Pharmaceuticals (SHPH), Cyclerion Therapeutics (CYCN), Hillstream BioPharma (HILS), Pulmatrix (PULM), Clever Leaves (CLVR), Virios Therapeutics (VIRI), Lixte Biotechnology (LIXT), and Universe Pharmaceuticals (UPC). These companies are all part of the "pharmaceutical preparations" industry.

Imunon vs.

Imunon (NASDAQ:IMNN) and Alzamend Neuro (NASDAQ:ALZN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, community ranking, media sentiment, profitability, dividends, risk and institutional ownership.

In the previous week, Imunon had 5 more articles in the media than Alzamend Neuro. MarketBeat recorded 7 mentions for Imunon and 2 mentions for Alzamend Neuro. Alzamend Neuro's average media sentiment score of 1.21 beat Imunon's score of -0.28 indicating that Alzamend Neuro is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Imunon
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
2 Very Negative mention(s)
Neutral
Alzamend Neuro
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Imunon has a beta of 1.69, meaning that its share price is 69% more volatile than the S&P 500. Comparatively, Alzamend Neuro has a beta of -0.13, meaning that its share price is 113% less volatile than the S&P 500.

Imunon's return on equity of -83.25% beat Alzamend Neuro's return on equity.

Company Net Margins Return on Equity Return on Assets
ImunonN/A -83.25% -57.05%
Alzamend Neuro N/A -612.26%-207.52%

Imunon received 2 more outperform votes than Alzamend Neuro when rated by MarketBeat users.

CompanyUnderperformOutperform
ImunonOutperform Votes
6
100.00%
Underperform Votes
No Votes
Alzamend NeuroOutperform Votes
4
100.00%
Underperform Votes
No Votes

Imunon presently has a consensus target price of $12.00, suggesting a potential upside of 971.43%. Alzamend Neuro has a consensus target price of $22.50, suggesting a potential upside of 2,400.00%. Given Alzamend Neuro's higher possible upside, analysts plainly believe Alzamend Neuro is more favorable than Imunon.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Imunon
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Alzamend Neuro
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

4.3% of Imunon shares are held by institutional investors. Comparatively, 6.4% of Alzamend Neuro shares are held by institutional investors. 3.8% of Imunon shares are held by company insiders. Comparatively, 10.9% of Alzamend Neuro shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Alzamend Neuro has lower revenue, but higher earnings than Imunon. Alzamend Neuro is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Imunon$500K21.06-$35.90M-$3.27-0.34
Alzamend NeuroN/AN/A-$14.88M-$1.51-0.61

Summary

Imunon beats Alzamend Neuro on 7 of the 13 factors compared between the two stocks.


Get Imunon News Delivered to You Automatically

Sign up to receive the latest news and ratings for IMNN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IMNN vs. The Competition

MetricImunonPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$10.53M$6.75B$4.99B$7.49B
Dividend YieldN/A2.82%2.87%3.87%
P/E Ratio-0.348.61181.9913.86
Price / Sales21.06220.612,948.7774.73
Price / CashN/A19.1095.9454.95
Price / Book0.274.764.484.66
Net Income-$35.90M$158.07M$114.14M$211.48M
7 Day Performance90.15%4.77%4.22%2.56%
1 Month Performance100.00%11.45%8.72%5.39%
1 Year Performance-19.42%5.41%12.07%8.65%

Imunon Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ALZN
Alzamend Neuro
2.5955 of 5 stars
$0.91
flat
$22.50
+2,372.5%
-88.8%$6.48MN/A-0.604Positive News
Gap Up
GNPX
Genprex
1.4948 of 5 stars
$4.24
-3.9%
N/A-91.6%$6.32MN/A-0.1731Short Interest ↑
SHPH
Shuttle Pharmaceuticals
1.5655 of 5 stars
$0.39
flat
N/A-79.2%$6.24MN/A-1.007Short Interest ↓
Gap Down
CYCN
Cyclerion Therapeutics
0 of 5 stars
$2.93
+1.0%
N/A-77.0%$7.16M$1.62M-0.5316Short Interest ↑
News Coverage
HILS
Hillstream BioPharma
0 of 5 stars
$0.41
+7.9%
N/A-62.8%$7.24MN/A-0.571News Coverage
PULM
Pulmatrix
1.9828 of 5 stars
$2.00
+2.6%
$10.00
+400.0%
-42.3%$7.30M$6.07M-0.4528Analyst Report
Short Interest ↑
CLVR
Clever Leaves
1.1937 of 5 stars
$4.18
-0.7%
N/A-66.8%$7.32M$17.80M-0.15400Short Interest ↓
VIRI
Virios Therapeutics
0.5108 of 5 stars
$0.38
+5.5%
N/A+23.7%$7.34MN/A-1.154Short Interest ↑
News Coverage
Gap Up
LIXT
Lixte Biotechnology
0 of 5 stars
$2.67
+20.8%
N/A-71.3%$6.01MN/A-0.813Short Interest ↑
News Coverage
Gap Down
High Trading Volume
UPC
Universe Pharmaceuticals
0 of 5 stars
$1.65
+3.1%
N/A-47.8%$5.97M$32.31M0.00225

Related Companies and Tools

This page (NASDAQ:IMNN) was last updated on 3/1/2024 by MarketBeat.com Staff